Sustained activation of renal N-methyl-D-aspartate receptors decreases vitamin D synthesis: a possible role for glutamate on the onset of secondary HPT

Autor/a

Parisi Capdevila, Eva

Bozic, Milica

Ibarz Escuer, Mercedes

Panizo García, Sara

Valcheva, Petya

Coll, Blai

Fernández i Giráldez, Elvira

Valdivielso Revilla, José Manuel

Data de publicació

2016-06-09T08:29:39Z

2025-01-01

2010



Resum

N-methyl-D-aspartate (NMDA) receptors (NMDAR) are tetrameric amino acid receptors that act as membrane calcium channels. The presence of the receptor has been detected in the principal organs responsible for calcium homeostasis (kidney, bone, and parathyroid gland), pointing to a possible role in mineral metabolism. The aim of this study was to test the effect of NMDAR activation in the kidney and on 1,25(OH)2D3 synthesis. We determined the presence of NMDAR subunits in HK-2 (human kidney cells) cells and proved its functionality. NMDA treatment for 4 days induced a decrease in 1 -hydroxylase levels and 1,25(OH)2D3 synthesis through the activation of the MAPK/ERK pathway in HK-2 cells. In vivo administration of NMDA for 4 days also caused a decrease in blood 1,25(OH)2D3 levels in healthy animals and an increase in blood PTH levels. This increase in PTH induced a decrease in the urinary excretion of calcium and an increase in urinary excretion of phosphorous and sodium as well as in diuresis. Bone turnover markers also increased. Animals with 5/6 nephrectomy showed low levels of renal 1 -hydroxylase as well as high levels of renal glutamate compared with healthy animals. In conclusion, NMDAR activation in the kidney causes a decrease in 1,25(OH)2D3 synthesis, which induces an increase on PTH synthesis and release. In animals with chronic kidney disease, high renal levels of glutamate could be involved in the downregulation of 1 -hydroxylase expression.


This work was supported by FIS PI09/0299, FIS PI07/0427, and REDINREN (16/06).

Tipus de document

article
publishedVersion

Llengua

Anglès

Matèries i paraules clau

Paratyroid hormone; Mitogen- activated protein kinase; Hyerparatyroidism

Publicat per

American Physiological Society

Documents relacionats

Reproducció del document publicat a https://doi.org/10.1152/ajpendo.00428.2010

AJP- Endocrinology and Metabolism, 2010, vol. 299, núm. 5, p. E825-E831

Drets

(c) American Physiological Society, 2010

Aquest element apareix en la col·lecció o col·leccions següent(s)